The real drug development delay? Bad communication.
Biotech ETFs can help investors capitalize on health care innovation while avoiding the boom-or-bust nature of individual ...
Call AI in biotech hype at your peril. There are real reasons that pharmaceutical companies are embracing this technology ...
Seeking biotech investment, breakthrough innovations, or a strategic gateway to the Asia-Pacific? The answers await in Hong Kong this September.HONG KONG, July 7, 2026 /PRNewswire/ -- The 5th Hong ...
David Craig’s operating manual for building biotech companies in today’s market is now available in hardcover and as an ...
Biotech companies are spending billions to perfect chemical formulas, only to be tripped up by the one variable they forgot ...
1mon
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.
As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results